A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00199290
Recruitment Status : Completed
First Posted : September 20, 2005
Last Update Posted : February 5, 2008
Information provided by:
Kaken Pharmaceutical

Brief Summary:
This study is designed to evaluate the efficacy and the safety of Trafermin(recombinant human basic fibroblast growth factor: rhbFGF) in Japanese patients with marginal periodontitis, in order to verify the superiority of Trafermin to placebo, and to determine the recommended therapeutic dose.

Condition or disease Intervention/treatment Phase
Periodontitis Drug: Trafermin (genetical recombination) Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 267 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and the Safety of Trafermin in Patients With Marginal Periodontitis in Japan
Study Start Date : August 2005
Actual Primary Completion Date : July 2007
Actual Study Completion Date : December 2007

Arm Intervention/treatment
Placebo Comparator: P Drug: Trafermin (genetical recombination)
Experimental: L
low dose (0.2 %)
Drug: Trafermin (genetical recombination)
Experimental: M
medium dose (0.3 %)
Drug: Trafermin (genetical recombination)
Experimental: H
high dose (0.4 %)
Drug: Trafermin (genetical recombination)

Primary Outcome Measures :
  1. rate of increase in alveolar bone height [ Time Frame: 36 weeks after administration ]

Secondary Outcome Measures :
  1. clinical attachment level regained [ Time Frame: 36 weeks after administration ]
  2. time course of increase rate in alveolar bone height [ Time Frame: within 36 weeks after administration ]
  3. time course of clinical attachment level regained [ Time Frame: within 36 weeks after administration ]
  4. occurrence and level of adverse reaction [ Time Frame: within 36 weeks after administration ]
  5. serum anti-Trafermin antibody level [ Time Frame: within 4 weeks ]
  6. serum Trafermin level [ Time Frame: within 24 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

The patient with marginal periodontitis intend to conduct a flap operation(modified Widman) must meet the following criteria:

  • Alveolar bone defect diagnosed by radiography.
  • Mobility of teeth must be <=2 and the width of attached gingiva is suitable for GTR(guided tissue regeneration) method.
  • Males and females, >=20 years of age.

Exclusion Criteria:

Patients will be excluded from the study if any of the following conditions are present:

  • Concomitant administration of adrenal cortical steroid within 4weeks of treatment in the trial.
  • Current or previous history of gingival overgrowth by drugs.
  • Current or previous history of cancer or malignant tumour.
  • Presence of diabetes mellitus(HbA1c>=6.5%)
  • Presence of malnutrition(serum albumin<=2g/dL)
  • Pregnancy or lactation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00199290

Kaken Investigational Site
Nagoya, Aichi, Japan, 464-8651
Kaken Investigational Site
Matsudo, Chiba, Japan, 271-8587
Kaken Investigational Site
Kitakyusyu, Fukuoka, Japan, 803-8580
Kaken Investigational Site
Mizuho, Gifu, Japan, 501-0296
Kaken Investigational Site
Ishikari-gun, Hokkaido, Japan, 061-0293
Kaken Investigational Site
Sapporo, Hokkaido, Japan, 060-8648
Kaken Investigational Site
Morioka, Iwate, Japan, 020-8505
Kaken Investigational Site
Yokohama, Kanagawa, Japan, 230-8501
Kaken Investigational Site
Sendai, Miyagi, Japan, 980-8575
Kaken Investigational Site
Suita, Osaka, Japan, 565-0871
Kaken Investigational Site
Bunkyo-ku, Tokyo, Japan, 113-8549
Kaken Investigational Site
Chiyoda-ku, Tokyo, Japan, 101-8310
Kaken Investigational Site
Machida, Tokyo, Japan, 194-0023
Kaken Investigational Site
Sinjyuku-ku, Tokyo, Japan, 160-8582
Kaken Investigational Site
Chiba, Japan, 261-0011
Kaken Investigational Site
Fukuoka, Japan, 812-8582
Kaken Investigational Site
Fukuoka, Japan, 814-0193
Kaken Investigational Site
Hiroshima, Japan, 734-8551
Kaken Investigational Site
Kagoshima, Japan, 890-8520
Kaken Investigational Site
Nagasaki, Japan, 852-8501
Kaken Investigational Site
Niigata, Japan, 951-8122
Kaken Investigational Site
Okayama, Japan, 700-8525
Kaken Investigational Site
Tokushima, Japan, 770-8503
Sponsors and Collaborators
Kaken Pharmaceutical
Study Director: Makoto Tamura, Ph.D Kaken Pharmaceutical Co.,Ltd. Identifier: NCT00199290     History of Changes
Other Study ID Numbers: KCB-1D-02
First Posted: September 20, 2005    Key Record Dates
Last Update Posted: February 5, 2008
Last Verified: February 2008

Keywords provided by Kaken Pharmaceutical:

Additional relevant MeSH terms:
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases